AUG 13, 2026 · JOURNAL ARTICLE
Long-Term Continuation therapy with Nab-Paclitaxel and Bevacizumab ± Anti-PD-1 in Advanced NSCLC: Case Reports and Mechanistic Insights：case report
Case Reports in Oncology
Two uncontrolled case reports with prolonged outcomes suggest a potential maintenance strategy, but lack comparator arms, prospective design, and power to establish efficacy or safety profiles.
Reported
Duration of treatment – Case 1more than 48 months
Duration of treatment – Case 224 months
Maximum grade of adverse events –…no grade ≥3